Kidney transplantation 2016: current status and potential challenges
|
|
- Kelly Richard
- 5 years ago
- Views:
Transcription
1 Kidney transplantation 2016: current status and potential challenges 15/12/2016 BVN-SBN : State-of-the-Art on Kidney Transplantation Patrick Peeters Ghent University Hospital, Belgium Challenges in 2016 and beyond Challenge N 1 2 native kidneys are still better than 1 transplanted kidney 1
2 Challenges in 2016 and beyond Challenge N 2 Less/older/worse donors Longer waiting times Older/sicker receptors About solid organ transplantions done in 2014: 1.8% increase over
3 3
4 Donation from deceased donors pmp Deceased donors in ET pmp 4
5 5
6 Living donor transplants 2015 in Belgium Kidney Liver Annual adjusted graft loss rates per 1,000 patients Cadaveric Living > <6 Pre-emptive Meier-Kriesche HU, et al. Transplantation 2002;74:
7 Effective DCD Euthanasie DCD IV DCD III DCD II n= 106 Median age of deceased donor in ET 7
8 Evolution of donor age in ET Age of effective donors in Belgium % 90% 80% 29,7 70% 60% 50% 40% 47, < 20 30% 20% 10% 0% ,7 4,4 Note number of donors 1994: 230 vs 2015: 315 8
9 Kidney waiting list 2015 Belgium Active WL Kidney waiting list 2015 Belgium Kidney en bloc Kidney Tx Active WL
10 = n 11/01/2017 Kidney waiting list 2015 Belgium Mortality Kidney en bloc Kidney Tx Active WL Removals from the ET waiting list 10
11 Challenges in 2016 and beyond CHALLENGE N 4 Graft function/loss Death with a functioning graft THE AXIS OF EVIL Cardiovascular disease Cancer Infections Causes of death and death rates in renal transplant patients United States Renal Data System. USRDS 2012 Annual Data Report 11
12 Freedom from BPAR (%) 11/01/2017 Individualized therapy progress Chapman Tx 2013 Freedom from BPAR at 12 months SYMPHONY trial 30 Standard-dose CsA (n=390) 20 Low-dose CsA (n=399) Low-dose tacrolimus (n=401) 10 CNI free (low-dose sirolimus; n=399) Months BPAR, biopsy-proven acute rejection; CsA, cyclosporin; CNI, calcineurin inhibitor Ekberg H et al. N Engl J Med 2007;357:
13 Do we do better?? ANZA data 2013 Chronic allograft dysfunction Pascual NEJM
14 Graft survival (%) 11/01/2017 egfr at 1 year post-transplant is a strong predictor of 5-year graft survival 5-year graft survival among patients with graft function at 1 year by egfr (ml/min/1.73 m 2 ) <90 45 <60 30 <45 15 <30 < Time post-transplant (months) Kidney-only transplant recipients, aged >18 years United States Renal Data System Annual Data Report egfr, estimated glomerular filtration rate (using Modification of Diet in Renal Disease equation) 2009, vol. 2, ch. 7, Association between CV death and serum creatinine at 1 year post-transplant Meier-Kriesche HU, et al. Transplantation 2003;75:
15 Death rate (per 100 patient-years) 11/01/2017 Adjusted patient survival for patients with a transplant and for patients after transplant loss Kaplan B, et al. Am J Transplant 2002;2:970 4 CVD is a leading cause of death with a functioning graft Retrospective analysis of ANZDATA between 1980 and ,0 1,8 1,6 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 1,8 1,7 1,2 1,1 1 0,9 0,8 0,7 0,7 0,7 0,6 0,6 0,7 0,7 0,5 0,4 0,4 0,4 0,4 0,4 0,4 0,3 0,3 0,3 Cardiovascular Malignancy Infection Other CVD, cardiovascular Pilmore disease HL et al. Transplantation 2010;89:
16 Death rate 11/01/2017 CVD death: time from transplant CVD death rates/100 patient-years according to time from transplant RR RR * * ** * * ** ** * RR 0.32 ** *** *** *p<0.05; **p<0.01; ***p<0.001 CVD, cardiovascular disease; RR, relative risk Time post-transplant (years) Pilmore HL et al. Transplantation 2010;89:851 7 Cardiovascular risk factors in transplant recipients Diabetes Hypertension Dyslipidaemia Smoking Pre-transplant low GFR proteinuria phosphate, calcium, PTH LVH, arterial stiffness anaemia Post-transplant NODAT low GFR Hypertension proteinuria Dyslipidaemia LVH Smoking Anaemia Increased age Inflammation Vascular disease GFR, glomerular filtration rate; PTH, parathyroid hormone; LVH, left ventricular hypertrophy; NODAT, new-onset diabetes after transplantation Rigatto C et al. J Am Soc Nephrol 2003;14:462 8; Ojo AO. Transplantation 2006;82:
17 RR a for ischaemic heart disease events >1 year post-kidney transplant 11/01/2017 Diabetes is a key risk factor for cardiovascular events after kidney transplantation Retrospective analysis of ischaemic heart disease in 1500 renal transplant patients between 1963 and 1997 at a single centre n= Diabetes Cholesterol BP 140/ mg/dl 159/99 mmhg Smoking a Compared to Framingham Heart Study database RR, relative risk; BP, blood pressure Kasiske BL et al. J Am Soc Nephrol 2000;11: NODAT is associated with 2-fold increase in death after kidney transplant Prospective 8-year analysis of 201 consecutive renal transplant ( ) patients at a single centre 100 Patient survival (%) a No diabetes (n=138) NODAT (n=35) Time since baseline (months) a Kaplan-Meier estimates NODAT, new-onset diabetes after transplantation Adapted from Hjelmesaeth J et al. Kidney Int 2006;69:
18 Patients free of 11/01/2017 NODAT has a strong impact on long-term CV outcomes: 3-fold increase in major cardiac events after kidney transplant Prospective 8-year analysis of 201 consecutive renal transplant ( ) patients at a single centre 100 cardiac events (%) a No diabetes (n=138) NODAT (n=35) Time since baseline (months) a Kaplan-Meier estimates NODAT, new-onset diabetes after transplantation; CV, cardiovascular Adapted from Hjelmesaeth J et al. Kidney Int 2006;69: The negative impact of post transplant cancer 2nd most common cause of death with a functioning graft AJT 2008; 8: Survival with cancer is extremely poor < 10% survival / 5 y CJASN 2008; 3:S P Peeters, M.D. Dept Nephrology - Ghent University Hospital, B Kuwait 18
19 Cumulative incidence skin cancer (%) 11/01/2017 Relative tumor risk after renal transplantation Cancer risk Cancer site RR All malignancy RR = 4.3 Small (RR > 2) Lung Bladder, urothel. Sarcoma Liver CNS Melanoma Cervix, vulva,vagina Intermediate (RR > 5) Thyroid Multiple myeloma PTLD (vs. NHL) Farynx, larynx High (RR > 15) Kidney Skin (non-melanotic) Kaposi sarcoma P Peeters, M.D. Dept Nephrology - Ghent University Hospital, B Kuwait Adapted from Wimmer CD et al, Kidney Int 2007; 71: 1271 Incidence of skin cancer increases over time Cumulative incidence of skin cancer in patients from Australia and the Netherlands CA in the Netherlands SCC in the Netherlands BCC in the Netherlands CA in Queensland SCC in Queensland BCC in Queensland Cumulative incidence of NMSCs ranges from 2 14% after 5 years 7 33% after 10 years Years of immunosuppression NMSC, non-melanomatous skin cancer; CA, all skin cancer; SCC, squamous-cell carcinoma; BCC, basal-cell carcinoma de Fijter JW. Nephrol Dial Transplant 2007;22(Suppl 1):i P Peeters, M.D. Dept Nephrology - Ghent University Hospital, B Kuwait 19
20 Risk factors associated with post-transplant malignancy Conventional Increasing age 1,2 Exposure to UV light 1 Previous exposure to carcinogens 1 Genetic predisposition 1,2 History of malignancy 1 Cigarette smoking 2 Analgesic abuse 2 Immunosuppressive regimen, eg CsA 3 or tacrolimus 6 Chronic viral infection 2 Previous treatment with cytotoxic agents, e.g. cyclophosphamide 2 Transmission of malignancy from donor 2 Levels of immune system components, eg high regulatory T-cells 4 MMP-26 and MMP-9 levels 5 Time after transplant 6 Duration of haemodialysis 6 Race 6 Transplant specific Age at time of transplant 6 UV, ultraviolet; CsA, cyclosporin; MMP, matrix metalloproteinase 1. Valantine H. J Heart Lung Transplant 2007;26:557 64; 2. Morath C et al. J Am Soc Nephrol 2004;15:1582 8; 3. Hojo M et al. Nature 1999;397:530 4; 4. Carroll RP et al. J Am Soc Nephrol 2010;21:713 22; 5. Kuivanen T et al. J Cutan Pathol 2009;36:929 36; 6. Imao T et al. Cancer 2007;109: P Peeters, M.D. Dept Nephrology - Ghent University Hospital, B Kuwait Infection risk Symphony Study Opportunistic infection p=0.03 CMV-infection p=0.003 Ekberg NEJM
21 Risk of Infectious Death Post Transplant: Impact of Allograft Function Meier-Kriesche Transplantation 2003 Challenges in 2016 and beyond CHALLENGE N 5 AMBR Common cause of death censored graft failure Dyscompliance vs. minimization 21
22 Post-transplant biopsy diagnosis Sellares AJT 2012;12: Causes of kidney transplant failure Sellares AJT 2012;12:
23 Wiebe AJT 2012;12: De novo DSA Wiebe AJT 2012;12:
24 Causes of kidney transplant failure Sellares AJT 2012;12: Early (< 3 m) vs. late acute ABMR after KTx Dörje Transplantation 2013; 94:
25 Challenges in 2016 and beyond CHALLENGE N 6 Biomarkers Biomarkers prediction of Acute Rejection AlloMap assay 20 genes mrna (NEJM 2014 Teuteberg) ksort assay 17 genes mrna (Plos Med 2014) Trugraf assay 200 transgenomic transscripts (AJT 2014) AlloSure donor derived free DNA (PNAS 2014 De Vlaminck) AUC 0.9 severe 0.83 moderate AR CXCL9-CXCL10 (Loupy JASN 2015) AUC 0.9 AR DSA + CXCL9-CXCL10 (Loupy JASN 2016) : better AUC 25
26 Challenges in 2016 and beyond CHALLENGE N 7 Tolerance Boston/Chicago/Stanford One-Study 26
27 Cause of death donors 2015 DBD vs. DCD 13% 10% 2% 3% 7% 18% 6% 6% 15% 11% 2% 1% 2% 2% 1% 2% 2% 24% 47% 19% 7% Anoxia / Strangulation Cerebral Ischemia Intoxication (suicide) Other Trauma (other) Cardiovascular ICB Meningitis Suicide (gunshot) Trauma (road accident) Anoxia / Strangulation Cerebral Ischemia Intoxication (suicide) Other Trauma (road accident) Euthanasie Cardiovascular ICB Meningitis Trauma (other) Tumor At least kidney transplantations done in 2014 performed in 99 countries 27
28 Kidney transplant waiting list ET 28
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More information8/07/2014. CCCN 2014 Renal transplantation. Plan of presentation. Casus: /06/ ATCD: 1. Indications. 2. Contra-indications.
CCCN 2014 Renal transplantation 28/06/2014 Patrick Peeters, M.D. Ghent University Hospital, Belgium Plan of presentation 1. Indications. 2. Contra-indications. 3. Allocation and donor aspects. 4. Patient
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationRisk Factors in Long Term Immunosuppressive Use and Advagraf. Daniel Serón Nephrology department Hospital Universitari Vall d Hebron
Risk Factors in Long Term Immunosuppressive Use and Advagraf Daniel Serón Nephrology department Hospital Universitari Vall d Hebron Progressive well defined diseases ABMR GN Polyoma Non-specific Findings
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationKidney Transplant Outcomes In Elderly Patients. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Kidney Transplant Outcomes In Elderly Patients Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case Discussion 70 year old Asian male, neuropsychiatrist, works full
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationTransplantation: Year in Review
Transplantation: Year in Review Alexander Wiseman, MD Medical Director, Kidney and Pancreas Transplant Program Associate Professor, Division of Renal Diseases and Hypertension University of Colorado Outline:
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationKidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.
Kidney Transplant in the Elderly! Robert Santella, M.D., F.A.C.P. Incident Rate of ESRD by Age Age 75+ 65-74 From US Renal Data System, 2012 Should there be an age limit? Various guidelines: Canadian,
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationDonation from Old Living Donors How safe is it? Safe for recipient or donor?
Donation from Old Living Donors How safe is it? Safe for recipient or donor? Pr Lionel Rostaing Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation CHU Grenoble Alpes France lrostaing@chu-grenoble.fr
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationHasan Fattah 3/19/2013
Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationTumours in the donor: what is the risk?
Tumours in the donor: what is the risk? Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta@on CHU Liège, University of Liege, Belgium olivier.detry@transplanta@on.be Financial Disclosure Research
More informationLong-term complications after kidney transplantation. Adnan Sharif
Long-term complications after kidney transplantation Adnan Sharif RA guidelines (2011) KDIGO guidelines (2009) Long-term complications after kidney transplantation ATC 2013 abstracts Outline Patient/Graft
More informationTransplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital
Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of
More informationEARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland
EARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Julio Pascal Hospital del Mar Nephrology Department Barcelona,
More informationFor more information about how to cite these materials visit
Author(s): Silas P. Norman, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationHow do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK?
How do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK? Dr Richard Baker & Professor Alan Jardine, co-authors, forthcoming Renal Association module on
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 09 Mar 2019 16:29:06 GMT) CTRI Number CTRI/2010/091/000679 [Registered on: 23/08/2010] - Last Modified On 10/07/2015 Post Graduate Thesis Type of Trial
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationA clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
More informationA clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
More informationTen-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly
Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly F. Vincenti, University of California, San Francisco G. Blancho, University
More informationKidney Transplantation in the Elderly. Kristian Heldal, MD, PhD Telemark Hospital Trust, Skien, Norway and University of Oslo
Kidney Transplantation in the Elderly Kristian Heldal, MD, PhD Telemark Hospital Trust, Skien, Norway and University of Oslo Agenda Background: Age and chronic kidney disease End stage kidney disease:
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationKIDNEY TRANSPLANTATION FOR THE INTERNIST. Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.
KIDNEY TRANSPLANTATION FOR THE INTERNIST Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.2018 Goal of Lecture: OUTLINE CKD -> ESRD Workup for Transplant
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationDiabetes Mellitus GUIDELINES UNGRADED SUGGESTIONS FOR CLINICAL CARE IMPLEMENTATION AND AUDIT BACKGROUND
Diabetes Mellitus Date written: November 2011 Author: Scott Campbell GUIDELINES a. We recommend that diabetes should not on its own preclude a patient from being considered for kidney transplantation (1D).
More informationCKD in Other Organ Transplants
CKD in Other Organ Transplants Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of Colorado
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationQuantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
More informationCurrent Trends in Kidney Transplantation: The Role of Nonadherence
Current Trends in Kidney Transplantation: The Role of Nonadherence Donald E. Hricik, MD Professor of Medicine Case Western Reserve University Chief of the Division of Nephrology and Hypertension Medical
More informationOverview. Evaluation of Potential Kidney Transplant Recipients. Projected Years of Life in Patients with ESRD
Evaluation of Potential Kidney Transplant Recipients Donald E. Hricik MD Professor of Medicine and Chief, Division of Nephrology and Hypertension University Hospitals Case Medical Center Conflict of Interest
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationCancer in the organ donor
Cancer in the organ donor Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta>on CHU Liège, University of Liege, Belgium olivier.detry@transplanta>on.be Conflicts of Interest Conflicts of Interest
More informationTransplant Webinar Series: Ep. 9 Biomarkers for Post-Transplant Immune Injury
Transplant Webinar Series: Ep. 9 Biomarkers for Post-Transplant Immune Injury Future Webinars Link to register: https://immucor.webinato.com/register All Content 2015 Immucor, Inc. Handouts http://www.immucor.com/en-us/pages/educational-
More informationRenal Transplant Registry Report 2008
Renal Transplant Registry Report 28 Contents:. Introduction Page 2. Summary of transplant activity 27-28 Page 2 3. Graft and Patient Survival analysis 989-28 Page 3 4. Acute rejection 989-28 Page 24. Comparison
More informationSimultaneous Pancreas Kidney Transplantation:
Simultaneous Pancreas Kidney Transplantation: What is the added advantage, and for whom? Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney
More informationRisk factors associated with the deterioration of renal function after kidney transplantation
Kidney International, Vol. 68, Supplement 99 (2005), pp. S113 S117 Risk factors associated with the deterioration of renal function after kidney transplantation DANIEL SERÓN, XAVIER FULLADOSA, and FRANCESC
More informationAre two better than one?
Are two better than one? Disclosures Ryutaro Hirose, MD Professor in Clinical Surgery University of California, San Francisco I have no relevant disclosures related to this presentation The PROBLEM There
More informationBack to dialysis after graft failure: Transplantectomy or not? Stop immunosuppression?
Back to dialysis after graft failure: Transplantectomy or not? Stop immunosuppression? Laurent WEEKERS CHU SartTilman Layout Introduction Epidemiology A note of caution on causality and bias Patient survival
More informationDonor Quality Assessment
Donor Quality Assessment Francesc Moreso, MD, PhD Renal Transplant Unit Hospital Universitari Vall d Hebron Barcelona. Spain 4/9/2017 Donor Quality Assessment 1 What is the problem? Across all age ranges,
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationOPTN/SRTR 2014 ANNUAL DATA REPORT
OPTN/SRTR 14 ANNUAL DATA REPORT KIDNEY A Hart 1, J M Smith 2,3, M A Skeans 3, S K Gustafson 3, D E Stewart 4,5, W S Cherikh 4,5, J L Wainright 4,5, G Boyle 4,5, J J Snyder 3,6, B L Kasiske 1,3, A K Israni
More informationTransplant Update New Kidney Allocation System Transplant Referral Strategies. Antonia Harford, MD University of New Mexico
Transplant Update New Kidney Allocation System Transplant Referral Strategies Antonia Harford, MD University of New Mexico Financial Disclosures Doctor Harford has received financial support for dialysis
More informationHBV, HCV, HIV and Kidney Transplantation. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
HBV, HCV, HIV and Kidney Transplantation Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Prevalence of hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationEffect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study
NDT Plus (2010) 3 [Suppl 2]: ii32 ii36 doi: 10.1093/ndtplus/sfq064 Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study Miguel Gonzalez-Molina 1, Miguel Angel
More informationFuture Webinars. Handouts 18/09/ Program-Handouts.aspx
Transplant Webinar Series: Ep. 9 Bio for Post-Transplant Immune Injury Future Webinars Link to register: https://immucor.webinato.com/register All Content 215 Immucor, Inc. Handouts http://www.immucor.com/en-us/pages/educational-
More informationchapter seven transplantation page
chapter seven There been times that I thought I couldn t last for long But now I think I m able to carry on It s been a long, a long time coming But I know a change gonna come, oh yes it will Sam Cooke,
More informationCHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster
CHAPTER 10 CANCER REPORT Jeremy Chapman and Angela Webster CANCER REPORT ANZDATA Registry 2004 Report This report summarises the cancer (excluding nonmelanocytic skin cancer) experience of patients treated
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationCancer in kidney transplant recipients: epidemiology and prevention
BTS 2018, Brighton Cancer in kidney transplant recipients: epidemiology and prevention Adnan Sharif Queen Elizabeth Hospital Birmingham Outline 1. The burden of cancer after kidney transplantation 2. Epidemiology
More informationMalignancy in Patients with Renal Insufficiency
XIVth Budapest Nephrology School Malignancy in Patients with Renal Insufficiency Michael Fischereder Nephrologisches Zentrum Medizinische Poliklinik Munich, Germany Questions How frequent are malignancies
More informationKIDNEY TRANSPLANTATION: THE BIG PICTURE
KIDNEY TRANSPLANTATION: THE BIG PICTURE Alden Doyle, MD, MS, MPH Aim To provide practical overview of the how kidney transplantation works and why it is an attractive option for patients with advanced
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationLong-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota
Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More information2017 BANFF-SCT Joint Scientific Meeting. Personalized Medicine in Liver Transplantation
2017 BANFF-SCT Joint Scientific Meeting Personalized Medicine in Liver Transplantation Miquel Navasa Liver Transplant Unit. Hospital Clínic. Barcelona. Barcelona, March 2017 Disclosures Consultant for
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya
CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal
More informationLe migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
More informationI hope the shared cared protocol will help with your care of this renal transplant patient. We are happy to discuss any issues with you.
Paediatric Nephrology Phone (64) 9-3078900 Fax (64) 9-3078938 renalnurse@adhb.govt.nz wwong@adhb.govt.nz tonyak@adhb.govt.nz stackm@adhb.govt.nz chanelp@adhb.govt.nz Dear Colleague, Thank you for resuming
More informationTransplantation simplified. Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK
Transplantation simplified Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK HISTORY The first successful kidney transplant was performed in 1954 between identical
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationF. Branco, V. Cavadas, L. Osório, F. Carvalho, L. Martins, L. Dias, A. Castro-Henriques, and E. Lima
The Incidence of Cancer and Potential Role of Sirolimus Immunosuppression Conversion on Mortality Among a Single-Center Renal Transplantation Cohort of 1,816 Patients F. Branco, V. Cavadas, L. Osório,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationHeart Transplant: State of the Art. Dr Nick Banner
Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression
More informationRejection or Not? Interhospital Renal Meeting 10 Oct Desmond Yap & Sydney Tang Queen Mary Hospital
Rejection or Not? Interhospital Renal Meeting 10 Oct 2007 Desmond Yap & Sydney Tang Queen Mary Hospital Case Presentation F/61 End stage renal failure due to unknown cause Received HD in private hospital
More informationBy the way, I have a transplant..
By the way, I have a transplant.. Transplant patient for non-transplant surgery David Elliott No relevant disclosures Organ donation in Australia - 2017 Survival rates following organ donation have increased
More informationSurvival of End Stage Renal Failure Patients with Cancer
Survival of End Stage Renal Failure Patients with Cancer Angela Webster Centre for Kidney Research, The Children s Hospital at Westmead Department of Renal Medicine, Westmead Hospital, NSW School of Public
More information